PE20170302A1 - Uso de pridopidina en dosis altas para el tratamiento de enfermedad de huntington - Google Patents

Uso de pridopidina en dosis altas para el tratamiento de enfermedad de huntington

Info

Publication number
PE20170302A1
PE20170302A1 PE2016002253A PE2016002253A PE20170302A1 PE 20170302 A1 PE20170302 A1 PE 20170302A1 PE 2016002253 A PE2016002253 A PE 2016002253A PE 2016002253 A PE2016002253 A PE 2016002253A PE 20170302 A1 PE20170302 A1 PE 20170302A1
Authority
PE
Peru
Prior art keywords
pridopidine
treatment
high doses
huntington disease
huntington
Prior art date
Application number
PE2016002253A
Other languages
English (en)
Inventor
Esther Lukasiewicz Hagai
Merav Bassan
Teige Wickenberg Anna Kristina Sveinsdotter
Eli Eyal
Original Assignee
Teva Pharmaceuticals Int Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=52105289&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PE20170302(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Teva Pharmaceuticals Int Gmbh filed Critical Teva Pharmaceuticals Int Gmbh
Publication of PE20170302A1 publication Critical patent/PE20170302A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/451—Non condensed piperidines, e.g. piperocaine having a carbocyclic group directly attached to the heterocyclic ring, e.g. glutethimide, meperidine, loperamide, phencyclidine, piminodine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Psychiatry (AREA)
  • Epidemiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychology (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

Se refiere a un metodo de tratamiento de un paciente humano afectado con enfermedad de Huntington que comprende la administracion periodica via oral de una composicion farmaceutica que comprende pridopidina o una sal farmaceuticamente aceptable de la misma, tal como clorhidrato; de tal manera que se administren mas de 135 mg de pridopidina al paciente al dia
PE2016002253A 2013-06-21 2014-06-19 Uso de pridopidina en dosis altas para el tratamiento de enfermedad de huntington PE20170302A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201361837928P 2013-06-21 2013-06-21
US201361877832P 2013-09-13 2013-09-13

Publications (1)

Publication Number Publication Date
PE20170302A1 true PE20170302A1 (es) 2017-03-31

Family

ID=52105289

Family Applications (2)

Application Number Title Priority Date Filing Date
PE2016002253A PE20170302A1 (es) 2013-06-21 2014-06-19 Uso de pridopidina en dosis altas para el tratamiento de enfermedad de huntington
PE2015002618A PE20160195A1 (es) 2013-06-21 2014-06-19 Uso de pridopidina en dosis altas para el tratamiento de enfermedad de huntington

Family Applications After (1)

Application Number Title Priority Date Filing Date
PE2015002618A PE20160195A1 (es) 2013-06-21 2014-06-19 Uso de pridopidina en dosis altas para el tratamiento de enfermedad de huntington

Country Status (24)

Country Link
US (1) US10322119B2 (es)
EP (1) EP3010506B1 (es)
JP (1) JP2016523862A (es)
KR (1) KR102316933B1 (es)
CN (1) CN105592848A (es)
AU (1) AU2014281414A1 (es)
BR (1) BR112015029918A2 (es)
CA (1) CA2913781C (es)
CL (1) CL2015003690A1 (es)
DK (1) DK3010506T3 (es)
EA (1) EA201690069A1 (es)
ES (1) ES2879631T3 (es)
HK (1) HK1221646A1 (es)
HU (1) HUE054783T2 (es)
IL (1) IL242804B (es)
MX (1) MX2015017307A (es)
PE (2) PE20170302A1 (es)
PH (1) PH12015502691A1 (es)
PL (1) PL3010506T3 (es)
SG (1) SG11201509729YA (es)
TW (1) TW201529069A (es)
UA (1) UA122999C2 (es)
UY (1) UY35624A (es)
WO (1) WO2014205229A1 (es)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
USRE46117E1 (en) 1999-12-22 2016-08-23 Teva Pharmaceuticals International Gmbh Modulators of dopamine neurotransmission
US20130197031A1 (en) 2010-09-03 2013-08-01 IVAX International GmbH Deuterated analogs of pridopidine useful as dopaminergic stabilizers
EP2787997A4 (en) 2011-12-08 2015-05-27 Ivax Int Gmbh HYDROBROMIDE SALT OF PRIDOPIDINE
US11090297B2 (en) 2013-06-21 2021-08-17 Prilenia Neurotherapeutics Ltd. Pridopidine for treating huntington's disease
CN106170287A (zh) * 2014-01-22 2016-11-30 梯瓦制药国际有限责任公司 改进释放的普利多匹定制剂
TW201613859A (en) 2014-06-30 2016-04-16 Teva Pharma Analogs of PRIDOPIDINE, their preparation and use
EP3236964A4 (en) 2014-12-22 2018-09-19 Teva Pharmaceuticals International GmbH L-tartrate salt of pridopidine
US11471449B2 (en) * 2015-02-25 2022-10-18 Prilenia Neurotherapeutics Ltd. Use of pridopidine to improve cognitive function and for treating Alzheimer's disease
EP3590512A1 (en) * 2015-02-25 2020-01-08 Prilenia Neurotherapeutics Ltd. Use of pridopidine to treat epilepsy
US20170020854A1 (en) * 2015-07-22 2017-01-26 Teva Pharmaceuticals International Gmbh Pridopidine base formulations and their use
AR105434A1 (es) 2015-07-22 2017-10-04 Teva Pharmaceuticals Int Gmbh Proceso para preparar pridopidina
ES2979123T3 (es) 2016-02-24 2024-09-24 Prilenia Neurotherapeutics Ltd Tratamiento de una enfermedad ocular neurodegenerativa usando pridopidina
JP6912574B2 (ja) * 2016-08-24 2021-08-04 プリレニア ニューロセラピューティクス リミテッド 機能低下を治療するためのプリドピジンの使用
EP3503890A4 (en) * 2016-08-24 2020-05-06 Prilenia Neurotherapeutics Ltd. USE OF PRIDOPIDINE FOR THE TREATMENT OF DYSTONIA
CA3036842A1 (en) * 2016-09-15 2018-03-22 Prilenia Therapeutics Development Ltd. Use of pridopidine for the treatment of anxiety and depression
ES2909557T3 (es) 2016-09-16 2022-05-09 Prilenia Neurotherapeutics Ltd Utilización de la pridopidina para el tratamiento del síndrome de Rett
US12102627B2 (en) 2016-09-16 2024-10-01 Prilenia Neurotherapeutics Ltd. Use of pridopidine for treating rett syndrome
CA3050700C (en) 2017-01-20 2023-10-03 Prilenia Neurotherapeutics Ltd. Use of pridopidine for the treatment of fragile x syndrome
ES2938546T3 (es) 2017-08-14 2023-04-12 Prilenia Neurotherapeutics Ltd Método de tratamiento de la esclerosis lateral amiotrófica con pridopidina
CN111278431A (zh) 2017-08-30 2020-06-12 普瑞尼亚神经治疗有限公司 普利多匹定的高浓度剂型
AU2018329628B2 (en) 2017-09-08 2021-04-22 Prilenia Neurotherapeutics Ltd. Pridopidine for treating drug induced dyskinesias
US12036213B2 (en) 2017-09-08 2024-07-16 Prilenia Neurotherapeutics Ltd. Pridopidine for treating drug induced dyskinesias
BR112021024744A2 (pt) * 2019-06-12 2022-03-22 Prilenia Neurotherapeutics Ltd Método para melhorar, manter ou reduzir o comprometimento da capacidade funcional e função motora de um paciente humano com doença de huntington
WO2021055443A1 (en) * 2019-09-17 2021-03-25 Hoffmann-La Roche Inc. Improvements in personalized healthcare for patients with movement disorders
US20230390232A1 (en) * 2020-10-28 2023-12-07 Buck Institute For Research On Aging N-propargylglycine: a unique inhibitor of proline dehydrogenase with brain-enhancing mitohormesis properties capable of mitigating the pathogenesis of neurodegenerative disorders

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
USRE46117E1 (en) 1999-12-22 2016-08-23 Teva Pharmaceuticals International Gmbh Modulators of dopamine neurotransmission
SE9904724D0 (sv) 1999-12-22 1999-12-22 Carlsson A Research Ab New modulators of dopamine neurotransmission I
EP1713486A4 (en) 2003-12-02 2009-04-29 Sheldon Leslie James COMBINED THERAPY FOR THE TREATMENT OF DEMENTIA, DEPRESSION AND APATHY
HUE029790T2 (hu) 2004-10-13 2017-04-28 Teva Pharmaceuticals Int Gmbh Eljárás 4-(3-metánszulfonil-fenil)-l-N-propil-piperidin elõállítására
EP1815857A1 (en) 2006-02-02 2007-08-08 LEK Pharmaceuticals D.D. A pharmaceutical composition comprising perindopril
CN101711236B (zh) 2007-04-12 2012-10-31 Nsab神经研究瑞典公司分公司 表现出改善的心血管副作用特性的多巴胺受体稳定剂/调节剂的n-氧化物和/或二-n-氧化物衍生物
WO2010008486A2 (en) 2008-06-24 2010-01-21 Parkinsons Institute Pluripotent cell lines and methods of use thereof
US8384755B2 (en) 2009-08-26 2013-02-26 Intouch Technologies, Inc. Portable remote presence robot
US20110206782A1 (en) 2010-02-24 2011-08-25 Auspex Pharmaceuticals, Inc. Piperidine modulators of dopamine receptor
WO2011107583A1 (en) * 2010-03-04 2011-09-09 Nsab, Filial Af Neurosearch Sweden Ab, Sverige Substituted 4-phenyl-n-alkyl-piperidines for preventing onset or slowing progression of neurodegenerative disorders
US20130197031A1 (en) 2010-09-03 2013-08-01 IVAX International GmbH Deuterated analogs of pridopidine useful as dopaminergic stabilizers
BR112014005389A8 (pt) 2011-09-07 2018-04-03 Ivax Int Gmbh Sal cloridrato de 4- (3-metanossulfonil-fenil) -1- propil-piperidina em uma forma cristalina, composição farmacêutica compreendendo o mesmo e usos do dito sal
EP2787997A4 (en) 2011-12-08 2015-05-27 Ivax Int Gmbh HYDROBROMIDE SALT OF PRIDOPIDINE
US9744155B2 (en) 2012-03-28 2017-08-29 Ixcela, Inc. IPA as a therapeutic agent, as a protective agent, and as a biomarker of disease risk
EA027748B1 (ru) 2012-04-04 2017-08-31 Тева Фармасьютикалз Интернэшнл Гмбх Применение придопидина в комбинации с тетрабеназином для лечения двигательных нарушений и ожирения
CA2884781A1 (en) 2012-09-27 2014-04-03 Teva Pharmaceutical Industries Ltd. Laquinimod and pridopidine for treating neurodegenerative disorders
EP2900226A4 (en) 2012-09-27 2016-03-30 Teva Pharma COMBINATION OF RASAGILIN AND PRIDOPIDIN FOR TREATING NEURODEGENERATIVE DISORDERS, ESPECIALLY HUNTINGTON'S DISEASE
CN106170287A (zh) 2014-01-22 2016-11-30 梯瓦制药国际有限责任公司 改进释放的普利多匹定制剂
TW201613859A (en) 2014-06-30 2016-04-16 Teva Pharma Analogs of PRIDOPIDINE, their preparation and use
EP3236964A4 (en) 2014-12-22 2018-09-19 Teva Pharmaceuticals International GmbH L-tartrate salt of pridopidine
WO2016138135A1 (en) 2015-02-25 2016-09-01 Teva Pharmaceuticals International Gmbh Sigma-1 receptor modulators for treating huntington's disease
EP3590512A1 (en) 2015-02-25 2020-01-08 Prilenia Neurotherapeutics Ltd. Use of pridopidine to treat epilepsy
AR105434A1 (es) 2015-07-22 2017-10-04 Teva Pharmaceuticals Int Gmbh Proceso para preparar pridopidina
US20170020854A1 (en) 2015-07-22 2017-01-26 Teva Pharmaceuticals International Gmbh Pridopidine base formulations and their use
WO2017048457A1 (en) 2015-09-18 2017-03-23 Teva Pharmaceuticals Industries Ltd. Combination of laquinimod and pridopidine to treat multiple sclerosis
JP6912574B2 (ja) 2016-08-24 2021-08-04 プリレニア ニューロセラピューティクス リミテッド 機能低下を治療するためのプリドピジンの使用
EP3503890A4 (en) 2016-08-24 2020-05-06 Prilenia Neurotherapeutics Ltd. USE OF PRIDOPIDINE FOR THE TREATMENT OF DYSTONIA
CA3036842A1 (en) 2016-09-15 2018-03-22 Prilenia Therapeutics Development Ltd. Use of pridopidine for the treatment of anxiety and depression
WO2018053275A1 (en) 2016-09-16 2018-03-22 Teva Pharmaceuticals International Gmbh Use of pridopidine for the treatment of familial dysautonomia
ES2909557T3 (es) 2016-09-16 2022-05-09 Prilenia Neurotherapeutics Ltd Utilización de la pridopidina para el tratamiento del síndrome de Rett

Also Published As

Publication number Publication date
AU2014281414A1 (en) 2016-01-21
WO2014205229A1 (en) 2014-12-24
CL2015003690A1 (es) 2016-10-28
EP3010506B1 (en) 2021-05-12
PH12015502691A1 (en) 2016-03-14
MX2015017307A (es) 2016-08-03
DK3010506T3 (da) 2021-07-12
PE20160195A1 (es) 2016-05-14
US20140378508A1 (en) 2014-12-25
CN105592848A (zh) 2016-05-18
IL242804B (en) 2022-02-01
UY35624A (es) 2015-01-30
BR112015029918A2 (pt) 2017-07-25
TW201529069A (zh) 2015-08-01
PL3010506T3 (pl) 2021-11-02
HUE054783T2 (hu) 2021-09-28
EP3010506A1 (en) 2016-04-27
CA2913781A1 (en) 2014-12-24
UA122999C2 (uk) 2021-02-03
JP2016523862A (ja) 2016-08-12
EA201690069A1 (ru) 2016-06-30
ES2879631T3 (es) 2021-11-22
HK1221646A1 (zh) 2017-06-09
SG11201509729YA (en) 2015-12-30
KR102316933B1 (ko) 2021-10-26
WO2014205229A8 (en) 2015-04-09
KR20160055122A (ko) 2016-05-17
CA2913781C (en) 2022-05-10
EP3010506A4 (en) 2017-02-08
US10322119B2 (en) 2019-06-18

Similar Documents

Publication Publication Date Title
PE20170302A1 (es) Uso de pridopidina en dosis altas para el tratamiento de enfermedad de huntington
CY1119490T1 (el) Παραγωγα πυραζολοπυρρολιδινης και η χρηση τους στην θεραπεια νοσηματων
CL2016001874A1 (es) Forma de dosificación oral sólida de liberación modificada que comprende pridopidina y un excipiente de control de velocidad; formulación farmacéutica que comprende a la forma de dosificación; uso de la forma de dosificación o de la formulación farmacéutica para tratar una enfermedad neurodegenerativa o relacionada con dopamina, como la enfermedad de huntington, entre otras.
PE20150161A1 (es) Uso de laquinimod de dosis alta para el tratamiento de esclerosis multiple
BR112015029491A2 (pt) derivados de imidazopirrolidinona e seu uso no tratamento de doença
MX2022003072A (es) Uso de pridopidina para el tratamiento de la disminucion funcional.
EA201270221A1 (ru) Лечение болезни крона с применением лаквинимода
NI201100147A (es) Métodos para tratar infartos agudos de miocardio y trastornos relacionados.
UA106636C2 (uk) Морфолінотіазоли як позитивні алостеричні модулятори альфа 7
JP2015532296A5 (es)
PE20181332A1 (es) Metodos de sedacion y formulacion parenteral para uso durante el tratamiento de cuidados criticos
CL2013002810A1 (es) Composicion farmaceutica solida oral que comprende a) un compuesto 2-amino-2-[2-(4-octil-fenil)-etil]-propano-1,3-diol (fingolimod) en una cantidad de 0,5 mg o menos, o una sal del mismo, b) un relleno y c) un estabilizante que comprende una ciclodextrina; y su uso para tratar una enfermedad autoinmune tal como esclerosis multiple.
NZ700924A (en) Dosage regimen for a pi-3 kinase inhibitor
CL2012003152A1 (es) Composicion farmaceutica para ser usada en terapia de reemplazo de glucocorticoides mediante la administracion oral una vez al dia de una dosis equivalente a la hidrocortizona de acuerdo con un nomograma de peso o un nomograma farmacocinetico; metodo de tratamiento; metodo para derivar una dosificacion individualizada.
AR098832A1 (es) Uso de laquinimod para retrasar la progresión de la enfermedad de huntington
AR079000A1 (es) Terapia anticancerosa dirigida a celulas madre cancerosas resistentes a las drogas
MX341660B (es) Agonista del receptor de ghrelina para el tratamiento de caquexia.
BR112014004339A2 (pt) suspensão oral
BR112014030288A8 (pt) composição farmacêutica, uso da mesma, e, uso de metanossulfonilacetonitrila
AR074246A1 (es) Derivados de 1-amino-alquilciclohexano para el tratamiento de trastornos del sueno
RU2010134265A (ru) Способ лечения диспепсии у телят
AR061046A1 (es) Mirtazapina para el tratamiento del dolor neuropatico
EA201592261A1 (ru) Фармацевтические композиции, включающие агомелатин в форме сокристаллов агомелатина с органической кислотой
BR112015028581A2 (pt) composição farmacêutica de dosagem baixa, utilização do ácido, método para o tratamento da doença inflamatória e composição farmacêutica
AR114012A1 (es) Método para proporcionar terapia de celiprolol a un paciente

Legal Events

Date Code Title Description
FA Abandonment or withdrawal